July 06, 2012 08:00 ET

Equity Research on Sequenom Inc. and Biogen Idec Inc. -- Biotechnology Industry Taking the Good With the Bad

NEW YORK, NY--(Marketwire - Jul 6, 2012) - has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Biotechnology industry and are offering free analytical research on Sequenom Inc. (NASDAQ: SQNM) and Biogen Idec Inc. (NASDAQ: BIIB). Register with us now to have free access to these research reports. Simply click on the link below.

Companies in the biotechnology industry, such as Sequenom Inc. and Biogen Idec Inc. have been facing both positive and negative trends over the last little while. One major challenge over the past few years has been the huge patent cliff which has seen a large number of lucrative patents expiring. Many industry players have been struggling with shrinking revenue streams as new products are not anticipated to bring in revenues of the same magnitude. Get your free reports on Sequenom Inc. and Biogen Idec Inc. at There is no commitment to join. is the Ultimate Trading Environment for investors. If you are considering owning Sequenom Inc. and Biogen Idec Inc. then you should sign up for a free membership and our complimentary reports today. Over the last 5 years our returns outpaced any of the major indexes. Sign up today by clicking on the link below to find out what you are missing.

Companies have been investing heavily in research and development in recent years but as time marches on, many are looking to partnerships, mergers and acquisitions as a way to access new products with lower investment in research and development. Biogen Idec is a good example of the aforementioned trend as it recently announced that it has entered into an exclusive worldwide option and collaboration agreement with Isis Pharmaceuticals Inc. to develop and commercialize a treatment for Steinert disease. Biogen Idec Inc. report is accessible for free by registering today at

On the plus side, evolving health challenges and increasing wealth in emerging markets continue to boost demand for new therapeutics and vaccines. As a result the Biotechnology industry has largely been outpacing other markets despite continued macroeconomic volatility. Sequenom Inc. report is accessible for free by registering today at

The two Biotechnology stocks research reports are available for free by signing up now on the link below.

Shine's Rooms is the brainchild of David Shine, a 13-year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting-edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link

Contact Information